$3.700
-0.010 (-0.27%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de SABS por análisis de gráficos similares
Alphio's SABS stock price prediction model matches the current SAB Biotherapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $3.78 (+2.06%). The 1-week path is $3.76 (+1.67%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de SAB Biotherapeutics Inc?
SAB Biotherapeutics Inc is a good buy right now due to its current price of $3.79, which is significantly lower than the average analyst price target of $12.75, suggesting a potential upside of over 235%. Additionally, the company has a strong cash position of $217.6 million, providing operational runway through 2028 despite recent losses. However, the main risk is the net loss of $22.49 million reported in Q2 2026, which highlights ongoing financial challenges.
SABS cerró en $3.70 el Tuesday, tras bajar -0.27%
SAB Biotherapeutics Inc (SABS) last closed at $3.7, losing -0.27%. These facts feed the 1-day and 1-week SABS price prediction above.
Factores de la previsión
Los factores de la previsión de SAB Biotherapeutics Inc (SABS) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de SABS, ordenadas por similitud.
Análisis de estacionalidad de SABS
Historically the probability of a positive September return for SABS is 0.00%. December offers the highest probability of a positive month at 37.21%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.